Notwithstanding promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable opposition from managed care entities. These insurers are frequently building limitations to reimbursement, such as steep cost restrictions and PA that restrict patient opportunity. Indust